Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research paper reviews the anti-androgenic properties of the drug flutamide and its metabolite Sch 16423 but presents no new experimental results.

Hormones and genetics play key roles in male and female baldness, which can affect mental health and may be linked to other health issues.

This study evaluated novel steroids' potential as future hormonal therapies for neuroprotection in glucose disorders, but emphasized that further research is needed to optimize androgen antagonist use in the context of COVID-19 progression.

This review discusses the prevalence and treatment of benign prostatic hyperplasia and reports no new findings; it emphasizes considering side effects and comorbidities in therapy choices.

This article updates a prior work on pharmacophore modeling and highlights the advances in 3D database searching technologies for drug design, without presenting new research findings.

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

This study demonstrates that patients with benign prostatic hyperplasia have a higher severity and frequency of male pattern baldness compared to a control group.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

This review discusses the potential of 4-azasteroids as 5α-reductase inhibitors for treating hirsutism, reporting their promising effects in animal studies but noting no clinical trials have been conducted yet.

This study found that both finasteride and a new steroidal compound, PM-9, competitively inhibit the 5α-reductase enzyme in Penicillium crustosum broth.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

In this review, the role of DHT in male-type obesity and metabolic diseases is discussed, with increased levels potentially exacerbating cardiovascular disease risk; the paper reports no new results.

This review explores cannabigerol (CBG) as a potential therapeutic agent with various pharmacological activities but reports no new clinical results, emphasizing the need for further research on its efficacy and safety.

This study found that the androgen precursors DHEA and androstenedione stimulated androgen-sensitive parameters in the sebaceous glands of the skin in castrated male hamsters.

This study examined the evolutionary and functional homology of steroid 5α-reductase and DET2 proteins, identifying protists as a common ancestor, and discovered a new subclass DET2-like in plants, potentially involved in polyprenol reduction.

This review explores the complex, context-dependent roles of tumor-secreted proteins and suggests that some proteins traditionally seen as tumor-promotive may act as tumor-suppressors in different environments, emphasizing the influence of cell fitness and treatment exposure.

This review discusses methods for improving study design and evaluation in sexual health literature and reports no new clinical results; it highlights current methodological issues and the benefits of validated questionnaires.

This study found that in patients undergoing allogeneic hematopoietic stem-cell transplantation, older age significantly increases the risk of hemorrhagic cystitis, especially in males, who are also affected by prostatic hyperplasia.

This review discusses the complex relationship between melasma and factors like female sex hormones, genetics, and ultraviolet light exposure, but reports no new clinical findings.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

This article discusses male pattern baldness and the potential of androgen inhibitors, reporting on previous findings and the need for new preventive measures; it does not present new clinical results.

This chapter reviews selective androgen receptor modulators, discussing their therapeutic potential beyond current androgen applications, and reports no new clinical findings.

Androstenedione, a hormone supplement, doesn't improve muscle or performance and can cause harmful side effects.

This study found that low doses of bisphenol A may increase proliferation of the ventral prostate in adult rats by altering the estrogen to androgen ratio and gene expression.

This study found that an earlier onset of androgenetic alopecia, especially in a frontal balding pattern, was significantly associated with an increased risk of prostate cancer among men at a Veterans Affairs Hospital.

This article discusses the hypothesis that mechanisms driving androgenic alopecia may reduce the risk and proliferation of prostate cancer by increasing prostaglandin D2 levels but presents no new clinical findings.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This study found that women with PCOS have higher total PSA levels than controls, and the total PSA level correlates positively with testosterone and free androgen index.

Finasteride treats hair loss but may affect prostate cancer detection.